【Press Release】The second Shonan Health Innovation Conference (SHIC) to be held in Boston
18 companies from Japan, South Korea, and Taiwan looking to partner with American VCs and CVCs

Press Release

Nov 13, 2025
iPark Institute Co., Ltd.

The second Shonan Health Innovation Conference (SHIC) to be held in Boston
18 companies from Japan, South Korea, and Taiwan looking to partner with American VCs and CVCs

●  21 VCs and CVCs with high expectations for Asian innovation will participate.
●  18 companies from Japan, South Korea, and Taiwan were selected through a rigorous screening process conducted by experts with experience in pharmaceutical business development.
●  9 finalists from the “Innovation Tiger 2025” pitch event will participate.
●  They will be joined in Boston by 9 companies from the public application pool.

iPark Institute Co., Ltd. (Headquarters: Fujisawa, Kanagawa; CEO: Toshio Fujimoto; hereinafter “iPark Institute”) has announced that the second Shonan Health Innovation Conference (hereinafter referred to as “SHIC”) will be held in Boston on November 20th, following the first conference held last year.

In order for startups to rapidly advance their research and development, it is essential to secure sufficient funding and collaborate with foreign investors. On the other hand, while foreign investors have high expectations for Asian innovation, it’s difficult for them to understand the investing environment in Asia, including Japan. To tackle this problem, iPark Institute is aiming to create an event for promising Asian startups to meet with foreign investors and offer support to help them secure funding from overseas.

【SHIC2025 Participating VC・CVC）】　(in no particular order)
As of Nov 12, 2025

【SHIC2025 Participating Teams】　(in no particular order)
As of Nov 12, 2025

iPark Institute CEO Toshio Fujimoto commented:
“We believe it to be very significant that we are able to hold the SHIC in Boston again this year. We hope that SHIC will become a hub for Asian startups and foreign investors to connect and serve as a launchpad for Asian innovation to the rest of the world.”

About iPark Institute Co., Ltd.
iPark Institute Co., Ltd. was established in 2023 with Industrial & Infrastructure Fund Investment Corporation (IIF), Takeda Pharmaceutical Company Limited (Takeda), and Mitsubishi Corporation as major shareholders. It took over the management of Shonan Health Innovation Park (Fujisawa City, Kanagawa Prefecture) in 2023, which Takeda has been responsible for since 2018. For more information about our company, please click here.

About Shonan Health Innovation Park (Shonan iPark)
Shonan iPark is Japan’s first pharmaceutical-initiated science park, created by Takeda Pharmaceutical Company Limited in April 2018 by opening its own research laboratories to the outside world. Currently operated by iPark Institute Co., Ltd. independent of Takeda Pharmaceutical Company Limited, the park aims to become a place where industry, government, and academia from a wide range of industries and sizes can come together to accelerate health innovation. Currently, the ecosystem is comprised of not only pharmaceutical companies, but also companies and organizations in next generation medicine, cellular agriculture, AI, and government, with approximately 190 companies and more than 2,500 people (as of November 2025).

Click here for homepage

For the latest information on tenants and member companies at Shonan iPark, click click here.

Official social links: YouTube / Facebook / X (former Twitter) / LinkedIn

For inquiries regarding this matter, please contact:
iPark Institute Co., Ltd., Communications
Attn: Sugita, Tsukahara
Mail: iPi.PR@shonan-ipark.com